Skip to content

Improving Adherence to Medication After Coronary Artery Bypass Surgery (CABG) in Older Adults

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02109523
Enrollment
288
Registered
2014-04-10
Start date
2014-03-31
Completion date
2016-02-29
Last updated
2023-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass Grafting (CABG) Surgery

Brief summary

Coronary artery bypass grafting (CABG) surgery is often performed in elderly patients, but non-adherence to post-CABG guideline medications is a common and serious clinical concern in this age group. A recent systematic review found that higher medication adherence significantly improved primary and secondary prevention of coronary artery disease outcomes in all the included studies. Another systematic review assessed studies published from 1999-2009 about motivational interviews, such as implementation intention, in relation to cardiovascular health. They found that motivational interview was an effective means of changing behavior, while offering promise in improving cardiovascular health status. The study is aimed to investigate effectiveness of long term volitional intervention in proving medication adherence in the CABG patient.

Interventions

BEHAVIORALMotivational Interviewing (MI

Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.

Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.

Sponsors

Qazvin University Of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 65 years or older * Undergoing Elective/subacute multivessel CABG * Able to give informed consent

Exclusion criteria

* Pregnant * Already using Dosette boxes (or similar) to improve their medication adherence * Currently enrolled in another clinical trial * Unable to attend required follow-up visits * Mini Mental Status Examination (MMSE) less than 20 * Significant dysphasia * Concomitant surgery * Myocardial infarction \<48h of surgery * Known platelet disease * Allergic to aspirin * Alcohol or narcotics abuse * Geographically not available for follow up * Ongoing bleeding * Missing written consent * Emergency surgery * Severe kidney disease (creatinine clearance \< 30 ml/min) * Oxygen-dependent chronic obstructive pulmonary disease * Active hepatitis * Significant hepatic failure * Prior peptic ulcer• Platelet count \< 150 E9 * Patient has terminal condition and may not survive until 6-month follow-up * Patient is a known participant in other RC studies * The inability to read and write Persian/Farsi * Participants who are not responsible for their own medication

Design outcomes

Primary

MeasureTime frame
changes in Patient-reported medication Adherence to four therapies (aspirin/antiplatelet; beta blocker; statin; ACE inhibitor)changes from baseline , 6 Months, 12 months and 18 months after the intervention
Changes in Percent of Patients Adherent to four therapies (aspirin/antiplatelet; beta blocker; statin; ACE inhibitor) Via Refill Recordschanges from baseline , 6 Months, 12 months and 18 months after the intervention

Secondary

MeasureTime frameDescription
Changes in coping planningchanges from baseline, 6 Months, 12 months and 18 months follow-upThe number of planning strategies is used by the patients before, at baseline, six months, twelve months and eighteen months after the intervention
Changes in quality of lifechanges from baseline, 6 Months, 12 months and 18 months follow-up
Mortality rate and Myocardial Infarctionchanges from baseline, 6 Months, 12 months and 18 months follow-up
Changes in Beliefs about Medicationschanges from baseline, 6 Months, 12 months and 18 months follow-up
Changes in Illness Perceptionschanges from baseline, 6 Months, 12 months and 18 months follow-up
Changes in psychological predictors of medication adherence (intention, perceived behavioral control and Self-monitoring)changes from baseline, 6 Months, 12 months and 18 months follow-up
Changes in total cholesterolchanges from baseline, 6 Months, 12 months and 18 months follow-up
Changes in blood pressurechanges from baseline, 6 Months, 12 months and 18 months follow-up
Changes in triglyceridechanges from baseline, 6 Months, 12 months and 18 months follow-up
Changes in high-density lipoproteins-cholesterolchanges from baseline, 6 Months, 12 months and 18 months follow-up
Changes in Low-density lipoproteins-cholesterolchanges from baseline, 6 Months, 12 months and 18 months follow-up
Changes in habit strengthchanges from baseline, 6 Months, 12 months and 18 months follow-upPatient's habits on medications use before, at baseline, six months, twelve months and eighteen months after the intervention
Changes in action planningchanges from baseline, 6 Months, 12 months and 18 months follow-upThe number of planning strategies is used by the patients before, at baseline, six months, twelve months and eighteen months after the intervention

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026